Allurion Technologies (NYSE:ALUR) - Aandelenkoers, Nieuws & Analyse

ALUR Overzicht aandelen

Allurion Technologies Inc. richt zich op het beëindigen van obesitas met een platform voor gewichtsverlies om mensen met overgewicht te behandelen.

Over het bedrijf

ALUR fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	1/6
Prestaties in het verleden	0/6
Financiële gezondheid	0/6
Dividenden	0/6

Beloningen

Revenue is forecast to grow 17.61% per year

Risicoanalyse

Has less than 1 year of cash runway

Negative shareholders equity

Earnings are forecast to decline by an average of 8.1% per year for the next 3 years

Does not have a meaningful market cap ($46M)

+ 3 meer risico's

Allurion Technologies Inc. Concurrenten

Beachbody Company

NYSE:BODI

US$41.5m

Regis

NasdaqGM:RGS

US$51.9m

Wag! Group

NasdaqGM:PET

US$34.4m

Junee

NasdaqCM:JUNE

US$62.3m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Allurion Technologies
Historische aandelenkoersen
Huidige aandelenkoers	US$0.71
52 Week Hoogtepunt	US$4.64
52 Week Laag	US$0.55
Bèta	-0.37
11 maand verandering	0.57%
3 maanden verandering	-1.39%
1 Jaar Verandering	-83.12%
33 jaar verandering	-89.72%
5 jaar verandering	n/a
Verandering sinds IPO	-89.73%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	ALUR	US Consumer Services	US Markt
7D	-6.0%	2.5%	-1.6%
1Y	-83.1%	21.3%	30.8%

Rendement versus industrie: ALUR underperformed the US Consumer Services industry which returned 20.8% over the past year.

Rendement versus markt: ALUR underperformed the US Market which returned 30.6% over the past year.

Prijsvolatiliteit

Is ALUR's price volatile compared to industry and market?
ALUR volatility
ALUR Average Weekly Movement	12.0%
Consumer Services Industry Average Movement	10.0%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: ALUR's share price has been volatile over the past 3 months compared to the US market.

Volatiliteit in de loop van de tijd: ALUR's weekly volatility has decreased from 27% to 12% over the past year, but is still higher than 75% of US stocks.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
n/a	503	Shantanu Gaur	www.allurion.com

Allurion Technologies Inc. richt zich op het beëindigen van obesitas met een platform voor gewichtsverlies om mensen met overgewicht te behandelen. Het platform, het Allurion Programma, bestaat uit een doorslikbare en procedure-loze intragastrische ballon voor gewichtsverlies (de Allurion Ballon), en biedt daarnaast toegang tot AI-bewakingstools voor patiënten op afstand, een eigen programma voor gedragsverandering, beveiligde berichtgeving en video telehealth die worden geleverd door de Allurion Virtual Care Suite. Allurion Technologies Inc. heeft zijn hoofdkantoor in Natick, Massachusetts.

Allurion Technologies Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Allurion Technologies zich tot de beurswaarde?
ALUR fundamentele statistieken
Marktkapitalisatie	US$45.65m
Inkomsten(TTM)	-US$37.64m
Inkomsten(TTM)	US$47.59m

1.0x

P/S-verhouding

-1.2x

Koers/Winstverhouding

Is ALUR overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ALUR resultatenrekening (TTM)
Inkomsten	US$47.59m
Kosten van inkomsten	US$11.33m
Brutowinst	US$36.26m
Overige uitgaven	US$73.90m
Inkomsten	-US$37.64m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Nov 13, 2024

Winst per aandeel (EPS)	-0.58
Brutomarge	76.19%
Nettowinstmarge	-79.10%
Schuld/Eigen Vermogen Verhouding	-113.3%

Hoe presteerde ALUR op de lange termijn?

Bekijk historische prestaties en vergelijking

ALUR Overzicht aandelen

Beloningen

Risicoanalyse

Allurion Technologies Inc. Concurrenten

NYSE:BODI

US$41.5m

NasdaqGM:RGS

US$51.9m

NasdaqGM:PET

US$34.4m

NasdaqCM:JUNE

US$62.3m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Allurion Technologies Inc. to Report Q3, 2024 Results on Nov 13, 2024

Allurion Technologies Inc., Annual General Meeting, Dec 11, 2024

Allurion Technologies, Inc. Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon

Allurion Technologies Receives Written Notice from the New York Stock Exchange Due to Non-Compliance with the Section 802.01B of the NYSE’s Listed Company Manual

Allurion Technologies, Inc. Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity

Allurion Technologies Inc. Announces the Appointment of Keith Johns to Its Board of Directors

Recent updates

Allurion Technologies Inc. to Report Q3, 2024 Results on Nov 13, 2024

Allurion Technologies Inc., Annual General Meeting, Dec 11, 2024

Allurion Technologies, Inc. Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon

Allurion Technologies Receives Written Notice from the New York Stock Exchange Due to Non-Compliance with the Section 802.01B of the NYSE’s Listed Company Manual

Allurion Technologies, Inc. Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity

Allurion Technologies Inc. Announces the Appointment of Keith Johns to Its Board of Directors

Allurion Technologies, Inc. Announces Publication of New Data Demonstrating Continued Weight Loss at One Year on the Allurion Program

Allurion Technologies Inc. Appoints Adrian Wild as Senior Vice President, International Commercial

Allurion Receives Continued Listing Standards Notice from NYSE

Allurion Technologies Inc. Updates Earnings Guidance for the Full Year 2024

Allurion Technologies Inc. to Report Q2, 2024 Results on Aug 13, 2024

New major risk - Shareholder dilution

Allurion Technologies Inc. has completed a Follow-on Equity Offering in the amount of $17.28781 million.

Allurion Technologies Inc. has filed a Follow-on Equity Offering.

Allurion Technologies Inc. has filed a Follow-on Equity Offering.

Allurion Technologies Inc. Appoints Ojas A. Buch as Chief Operating Officer

Allurion Technologies, Inc. Announces Expansion of AI Weight Loss Coach to Support Patients on GLP-1s

First quarter 2024 earnings released: EPS: US$0.12 (vs US$1.70 loss in 1Q 2023)

Allurion Technologies Inc. Reiterates Revenue Guidance for the Year 2024

Allurion Technologies Inc. to Report Q1, 2024 Results on May 14, 2024

Allurion Technologies Inc. Provides Preliminary Earnings Guidance for the First Quarter 2024

Allurion Technologies Inc. announced that it has received $48 million in funding from RTW Investments, LP

Allurion Technologies Inc. announced that it has received $48 million in funding from RTW Investments, LP

Allurion Technologies, Inc. Expands Virtual Care Suite to the United States

Allurion Technologies Inc. Reiterates Earnings Guidance for the Full Year 2024

Full year 2023 earnings released: US$2.27 loss per share (vs US$1.51 loss in FY 2022)

New minor risk - Market cap size

New minor risk - Share price stability

Allurion Technologies Inc. Appoints Milena Alberti-Perez as Board of Directors as Audit Committee Chair

Allurion Technologies Inc. to Report Q4, 2023 Results on Mar 21, 2024

New minor risk - Shareholder dilution

Allurion Technologies Inc. Appoints Brendan Gibbons as Its New Chief Legal Officer and Corporate Secretary

Allurion Technologies Inc. Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year of 2023 and Full Year of 2024

Allurion Technologies Inc. Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year of 2023 and Full Year of 2024

Allurion Technologies Inc. Announces New Research Highlights the Positive Impact of GLP-1s and Other Anti-Obesity Medications on the Allurion Program

Third quarter 2023 earnings released

Allurion Technologies Inc. to Report Q3, 2024 Results on Nov 13, 2023

Allurion Technologies, Inc. Completes Enrollment in Pivotal AUDACITY Trial for the Allurion Balloon

Second quarter 2023 earnings released

No independent directors

Allurion Technologies Inc. completed the acquisition of Compute Health Acquisition Corp. (NYSE:CPUH) from Compute Health Sponsor LLC and other in a reverse merger transaction.

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Allurion Technologies Inc. Samenvatting

1.0x

-1.2x

Inkomsten en omzet